Experimental Breast Cancer Drug Extends Lives By Months
06.07.10 |
A breast cancer drug made from sea sponges can increase the lifespan of cancer patients by months, even when chemotherapy fails. An international research team has announced that the drug Eribulin added an average of two-and-a-half-months to the lives of breast cancer patients whose cancer had returned. The drug was tested in 762 breast cancer patients with different types of tumors. All had cancer that spread and all had undergone at least two rounds of chemotherapy. In a blind test, patients given Eribulin fared considerably better than those given a placebo.
Most cancer drug trials look to see if tumors shrink or start growing back. This was the first study to compare overall survival using a new drug in patients who'd already been treated for metastatic breast cancer. In an era in which researchers are looking at targeted therapies, Eribulin may be one of the last new chemotherapy drugs that target fast-growing cells but also kill healthy cells.
CATEGORIES
AUTHORS
ARCHIVE BY MONTH
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008